On Monday, GeneDx Holdings got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.
The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The market's biggest winners often have a 95 or higher rating in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
GeneDx Holdings is not currently near a proper buy zone. Look for the stock to form and break out of a new chart pattern.
Lean How — And When — To Sell Stocks
The stock has an 80 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of D shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
The company posted a 0% rise in earnings for Q4. Top line growth rose 67%, up from 44% in the prior report. That marks one quarter of increasing revenue increases.
GeneDx Holdings earns the No. 9 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Halozyme Therapeutics are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
